Brief: Checkpoint Therapeutics Submits Biologics License Application To FDA For Carcinoma Drug Cosibelimab
04/01/2023 13:24
Jan 4 (Reuters) - Checkpoint Therapeutics Inc CKPT.O :
* CHECKPOINT THERAPEUTICS SUBMITS BIOLOGICS LICENSE
APPLICATION TO
FDA FOR COSIBELIMAB AS A TREATMENT FOR PATIENTS WITH METASTATIC
OR LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
Source text for Eikon: ID:nGNX1jbJZw
Further company coverage: CKPT.O
((Reuters.Briefs@thomsonreuters.com
))
Recent news on Checkpoint Therapeutics
See all newsCheckpoint Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Checkpoint Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Street View -India's Sun Pharma buying Checkpoint boosts its specialty portfolio, analysts say